{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:33:59Z","timestamp":1790847239218,"version":"4.1.0"},"reference-count":148,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,26]],"date-time":"2025-01-26T00:00:00Z","timestamp":1737849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>MAGE A4 (Melanoma Antigen Gene A4) is a cancer testis antigen (CTA) that is expressed normally in germline cells (testis\/embryonic tissues) but absent in somatic cells. The MAGE A4 CTA is expressed in a variety of tumor types, like synovial sarcoma, ovarian cancer and non-small cell lung cancer. Having its expression profile limited to germline cells has made MAGE A4 a sought-after immunotherapeutic target in certain malignancies. In this review, we focus on MAGE-A4\u2019s function and expression, current clinical trials involving targeted immunotherapy approaches, and challenges and opportunities facing MAGE-A4\u2019s targeted therapeutics.<\/jats:p>","DOI":"10.3390\/cancers17030413","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T07:46:29Z","timestamp":1737963989000},"page":"413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Adoptive T Cell Therapy Targeting MAGE-A4"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3309-1669","authenticated-orcid":false,"given":"Kapil","family":"Chandora","sequence":"first","affiliation":[{"name":"Morehouse School of Medicine, 720 Westview Dr, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay","family":"Chandora","sequence":"additional","affiliation":[{"name":"Morehouse School of Medicine, 720 Westview Dr, Atlanta, GA 30310, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15232, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludimila","family":"Cavalcante","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, University of Virginia Comprehensive Cancer Center, Charlottesville, VA 22903, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1080\/14712598.2019.1608179","article-title":"Facing the Future: Challenges and Opportunities in Adoptive T Cell Therapy in Cancer","volume":"19","author":"Magalhaes","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/nrc1167","article-title":"Adoptive-Cell-Transfer Therapy for the Treatment of Patients with Cancer","volume":"3","author":"Dudley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.4049\/jimmunol.179.9.5845","article-title":"High-Affinity TCRs Generated by Phage Display Provide CD4+ T Cells with the Ability to Recognize and Kill Tumor Cell Lines","volume":"179","author":"Zhao","year":"2007","journal-title":"J. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer Regression in Patients after Transfer of Genetically Engineered Lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.3747\/co.27.5283","article-title":"Chimeric Antigen Receptor T Cell Therapy Comes to Clinical Practice","volume":"27","author":"Wall","year":"2020","journal-title":"Curr. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the Uneven Road of Antigen Heterogeneity in Solid Tumors","volume":"51","author":"Chen","year":"2018","journal-title":"Curr. Opin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T Cell Killing Requires the IFN\u03b3R Pathway in Solid but Not Liquid Tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s43018-020-0038-2","article-title":"Bystander IFN-\u03b3 Activity Promotes Widespread and Sustained Cytokine Signaling Altering the Tumor Microenvironment","volume":"1","author":"Thibaut","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nrc3565","article-title":"Gene-Engineered T Cells for Cancer Therapy","volume":"13","author":"Kershaw","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/(SICI)1097-0215(19981029)78:3<387::AID-IJC22>3.0.CO;2-2","article-title":"Expression of Multiple Cancer\/Testis (CT) Antigens in Breast Cancer and Melanoma: Basis for Polyvalent CT Vaccine Strategies","volume":"78","author":"Sahin","year":"1998","journal-title":"Int. J. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2217\/1750743X.1.1.19","article-title":"MAGE A3 Antigen-Specific Cancer Immunotherapeutic","volume":"1","author":"Peled","year":"2009","journal-title":"Immunotherapy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/jcp.21380","article-title":"Cancer Testis Antigens in Human Melanoma Stem Cells: Expression, Distribution, and Methylation Status","volume":"215","author":"Sigalotti","year":"2008","journal-title":"J. Cell. Physiol."},{"key":"ref_15","first-page":"6682","article-title":"MAGE-A Gene Expression Pattern in Primary Breast Cancer","volume":"61","author":"Otte","year":"2001","journal-title":"Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"8055","DOI":"10.1158\/1078-0432.CCR-05-1203","article-title":"Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer","volume":"11","author":"Gure","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3892\/ijmm.2012.896","article-title":"Pattern of Cancer\/Testis Antigen Expression in Lung Cancer Patients","volume":"29","author":"Kim","year":"2012","journal-title":"Int. J. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/CJI.0000000000000013","article-title":"Expression of MAGE-A3\/6 in Primary Breast Cancer Is Associated with Hormone Receptor Negative Status, High Histologic Grade, and Poor Survival","volume":"37","author":"Ayyoub","year":"2014","journal-title":"J. Immunother."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/nrc1669","article-title":"Cancer\/Testis Antigens, Gametogenesis and Cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"ref_20","first-page":"3982","article-title":"Myeloid-derived Suppressor Cells Infiltration in Non-small-cell Lung Cancer Tumor and MAGE-A4 and NY-ESO-1 Expression","volume":"19","author":"Hou","year":"2020","journal-title":"Oncol. Lett."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.1007\/s00432-022-04514-z","article-title":"Combinational Expression of Tumor Testis Antigens NY-ESO-1, MAGE-A3, and MAGE-A4 Predicts Response to Immunotherapy in Mucosal Melanoma Patients","volume":"149","author":"Freiberger","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1200\/JCO.2010.32.2537","article-title":"Tumor Regression in Patients with Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive with NY-ESO-1","volume":"29","author":"Robbins","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_23","first-page":"A1","article-title":"959 Safety and Anti-Tumor Activity of TCR-Engineered Autologous, PRAME-Directed T Cells across Multiple Advanced Solid Cancers at Low Doses\u2014Clinical Update on the ACTengine\u00ae IMA203 Trial","volume":"9","author":"Wermke","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1126\/science.1840703","article-title":"A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma","volume":"254","author":"Traversari","year":"1991","journal-title":"Science"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1074\/mcp.M112.019786","article-title":"Proteomic Profiling of Triple-Negative Breast Carcinomas in Combination with a Three-Tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer","volume":"12","author":"Gromova","year":"2013","journal-title":"Mol. Cell. Proteom. MCP"},{"key":"ref_26","first-page":"509","article-title":"Frequent Cytolytic T-Cell Responses to Peptide MAGE-A10(254-262) in Melanoma","volume":"61","author":"Valmori","year":"2001","journal-title":"Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00262-006-0228-5","article-title":"Molecular and Immunological Evaluation of the Expression of Cancer\/Testis Gene Products in Human Colorectal Cancer","volume":"56","author":"Alves","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/sj.bjc.6604476","article-title":"MAGE-A Protein and MAGE-A10 Gene Expressions in Liver Metastasis in Patients with Stomach Cancer","volume":"99","author":"Suzuki","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1002\/ijc.27914","article-title":"MAGE-A10 Cancer\/Testis Antigen Is Highly Expressed in High-Grade Non-Muscle-Invasive Bladder Carcinomas","volume":"132","author":"Mengus","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10362","DOI":"10.1158\/0008-5472.CAN-10-1341","article-title":"Mage-A Cancer\/Testis Antigens Inhibit P53 Function by Blocking Its Interaction with Chromatin","volume":"70","author":"Marcar","year":"2010","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12105","DOI":"10.1038\/ncomms12105","article-title":"A Neomorphic Cancer Cell-Specific Role of MAGE-A4 in Trans-Lesion Synthesis","volume":"7","author":"Gao","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/71600","article-title":"Reduced Stability of Retinoblastoma Protein by Gankyrin, an Oncogenic Ankyrin-Repeat Protein Overexpressed in Hepatomas","volume":"6","author":"Higashitsuji","year":"2000","journal-title":"Nat. Med."},{"key":"ref_33","first-page":"13","article-title":"Gankyrin Oncoprotein: Structure, Function, and Involvement in Cancer","volume":"4","author":"Li","year":"2010","journal-title":"Curr. Chem. Biol."},{"key":"ref_34","first-page":"3530","article-title":"Expression of Gene MAGE-A4 in Reed-Sternberg Cells","volume":"95","author":"Chambost","year":"2000","journal-title":"Blood"},{"key":"ref_35","first-page":"6453","article-title":"Expression of the MAGE-A4 and NY-ESO-1 Cancer-Testis Antigens in Serous Ovarian Neoplasms","volume":"9","author":"Yakirevich","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00428-017-2206-z","article-title":"MAGEA4 expression in bone and soft tissue tumors: Its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1","volume":"471","author":"Iura","year":"2017","journal-title":"Virchows Arch."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/j.1349-7006.2009.01303.x","article-title":"Cancer\/Testis (CT) Antigens: Potential Targets for Immunotherapy","volume":"100","author":"Caballero","year":"2009","journal-title":"Cancer Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and Neck Squamous Cell Carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5442","DOI":"10.1158\/1078-0432.CCR-06-0527","article-title":"Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma","volume":"12","author":"Sharma","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_40","first-page":"3937","article-title":"Immunohistochemical Expression and Clinicopathological Assessment of the Cancer Testis Antigens NY-ESO-1 and MAGE-A4 in High-Grade Soft-Tissue Sarcoma","volume":"17","author":"Kakimoto","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0952-7915(97)80053-2","article-title":"Serological Identification of Human Tumor Antigens","volume":"9","author":"Sahin","year":"1997","journal-title":"Curr. Opin. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/cjp2.16","article-title":"Cancer-Testis Antigens PRAME and NY-ESO-1 Correlate with Tumour Grade and Poor Prognosis in Myxoid Liposarcoma","volume":"1","author":"Iura","year":"2015","journal-title":"J. Pathol. Clin. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1002\/cncr.26486","article-title":"Cancer-Testis Antigens Expressed in Osteosarcoma Identified by Gene Microarray Correlate with a Poor Patient Prognosis","volume":"118","author":"Zou","year":"2012","journal-title":"Cancer"},{"key":"ref_44","first-page":"3971","article-title":"Combined Use of Oligonucleotide and Tissue Microarrays Identifies Cancer\/Testis Antigens as Biomarkers in Lung Carcinoma1","volume":"62","author":"Sugita","year":"2002","journal-title":"Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1002\/(SICI)1521-4141(199910)29:10<3329::AID-IMMU3329>3.0.CO;2-7","article-title":"A MAGE-A4 Peptide Presented by HLA-A2 Is Recognized by Cytolytic T Lymphocytes","volume":"29","author":"Duffour","year":"1999","journal-title":"Eur. J. Immunol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1073\/pnas.91.6.2105","article-title":"Induction of Anti-Tumor Cytotoxic T Lymphocytes in Normal Humans Using Primary Cultures and Synthetic Peptide Epitopes","volume":"91","author":"Celis","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1084\/jem.173.1.273","article-title":"Human T Lymphocytes Recognize a Peptide of Single Point-Mutated, Oncogenic Ras Proteins","volume":"173","author":"Jung","year":"1991","journal-title":"J. Exp. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1682381","DOI":"10.1080\/2162402X.2019.1682381","article-title":"Preclinical Evaluation of an Affinity-Enhanced MAGE-A4-Specific T-Cell Receptor for Adoptive T-Cell Therapy","volume":"9","author":"Sanderson","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-14-1559","article-title":"Adoptive Transfer of MAGE-A4 T-Cell Receptor Gene-Transduced Lymphocytes in Patients with Recurrent Esophageal Cancer","volume":"21","author":"Kageyama","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13073-016-0335-7","article-title":"Single-Cell TCRseq: Paired Recovery of Entire T-Cell Alpha and Beta Chain Transcripts in T-Cell Receptors from Single-Cell RNAseq","volume":"8","author":"Redmond","year":"2016","journal-title":"Genome Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1158\/1078-0432.CCR-08-1638","article-title":"Characterization of Genetically Modified T-Cell Receptors That Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells","volume":"15","author":"Parkhurst","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and Persistence of Adoptively Transferred Autologous CD19-Targeted T Cells in Patients with Relapsed or Chemotherapy Refractory B-Cell Leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4049\/jimmunol.169.3.1241","article-title":"T Cell Proliferation Induced by Autologous Non-T Cells Is a Response to Apoptotic Cells Processed by Dendritic Cells","volume":"169","author":"Chernysheva","year":"2002","journal-title":"J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1002\/eji.201847659","article-title":"Targeting Treg Cells in Cancer Immunotherapy","volume":"49","author":"Tanaka","year":"2019","journal-title":"Eur. J. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1084\/jem.186.8.1223","article-title":"Survival of Mature CD4 T Lymphocytes Is Dependent on Major Histocompatibility Complex Class II\u2013Expressing Dendritic Cells","volume":"186","author":"Brocker","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.cell.2007.01.048","article-title":"How a Single T Cell Receptor Recognizes Both Self and Foreign MHC","volume":"129","author":"Colf","year":"2007","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"De, R.K., and Tomar, N. (2014). T-Cell Epitope Prediction Methods: An Overview. Immunoinformatics, Springer. Methods in Molecular Biology.","DOI":"10.1007\/978-1-4939-1115-8"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Paul, S., Croft, N.P., Purcell, A.W., Tscharke, D.C., Sette, A., Nielsen, M., and Peters, B. (2020). Benchmarking Predictions of MHC Class I Restricted T Cell Epitopes in a Comprehensively Studied Model System. PLoS Comput. Biol., 16.","DOI":"10.1371\/journal.pcbi.1007757"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1016\/j.vaccine.2014.09.002","article-title":"High Expression of MAGE-A4 and MHC Class I Antigens in Tumor Cells and Induction of MAGE-A4 Immune Responses Are Prognostic Markers of CHP-MAGE-A4 Cancer Vaccine","volume":"32","author":"Saito","year":"2014","journal-title":"Vaccine"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T Cell Therapy for MAGE-A4 Solid Cancers in HLA-A*02 Patients: A Phase 1 Trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1200\/JCO.2020.38.15_suppl.102","article-title":"Phase I Dose Escalation and Expansion Trial to Assess the Safety and Efficacy of ADP-A2M4 SPEAR T Cells in Advanced Solid Tumors","volume":"38","author":"Hong","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"11504","DOI":"10.1200\/JCO.2021.39.15_suppl.11504","article-title":"SPEARHEAD-1: A Phase 2 Trial of Afamitresgene Autoleucel (Formerly ADP-A2M4) in Patients with Advanced Synovial Sarcoma or Myxoid\/Round Cell Liposarcoma","volume":"39","author":"Attia","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_64","unstructured":"Roche, H.L. (2023, December 31). An Open-Label, Multicenter, Phase I Study to Evaluate Safety, Pharmacokinetics, and Preliminary Anti-Tumor Activity of RO7444973 in Participants with Unresectable and\/or Metastatic MAGE-A4-Positive Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05129280."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"ltac005","DOI":"10.1093\/immadv\/ltac005","article-title":"Combination of Genetically Engineered T Cells and Immune Checkpoint Blockade for the Treatment of Cancer","volume":"2","author":"Rossetti","year":"2022","journal-title":"Immunother. Adv."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"eabd5515","DOI":"10.1126\/sciimmunol.abd5515","article-title":"Bispecific Antibodies Targeting Mutant RAS Neoantigens","volume":"6","author":"Douglass","year":"2021","journal-title":"Sci. Immunol."},{"key":"ref_67","first-page":"A1","article-title":"379 Initial Safety, Efficacy, and Product Attributes from the SURPASS Trial with ADP-A2M4CD8, a SPEAR T-Cell Therapy Incorporating an Affinity Optimized TCR Targeting MAGE-A4 and a CD8\u03b1 Co-Receptor","volume":"8","author":"Hong","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"TPS363","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS363","article-title":"SURPASS-2 Trial Design: A Phase 2, Open-Label Study of ADP-A2M4CD8 SPEAR T Cells in Advanced Esophageal or Esophagogastric Junction Cancers","volume":"40","author":"Hong","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"S685","DOI":"10.1016\/j.annonc.2020.08.1091","article-title":"976TiP SPEARHEAD-2 Trial Design: A Phase II Pilot Trial of ADP-A2M4 in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Cancer","volume":"31","author":"Cohen","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"TPS3165","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3165","article-title":"A Phase I\/II First-in-Human Study of a Novel Anti-MAGE-A4 TCR\/Anti-CD3 Bispecific (IMC-C103C) as Monotherapy and in Combination with Atezolizumab in HLA-A*02:01-Positive Patients with MAGE-A4-Positive Advanced Solid Tumors (IMC-C103C-101)","volume":"38","author":"Blumenschein","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1200\/JCO.2008.16.5449","article-title":"Adoptive Cell Therapy for Patients with Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens","volume":"26","author":"Dudley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nrm2236","article-title":"The Third Dimension Bridges the Gap between Cell Culture and Live Tissue","volume":"8","author":"Pampaloni","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"Afamitresgene Autoleucel for Advanced Synovial Sarcoma and Myxoid Round Cell Liposarcoma (SPEARHEAD-1): An International, Open-Label, Phase 2 Trial","volume":"403","author":"Araujo","year":"2024","journal-title":"Lancet"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1007\/s40291-024-00749-3","article-title":"Afamitresgene Autoleucel: First Approval","volume":"28","author":"Keam","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e002035","DOI":"10.1136\/jitc-2020-002035","article-title":"Development of a CD8 Co-Receptor Independent T-Cell Receptor Specific for Tumor-Associated Antigen MAGE-A4 for next Generation T-Cell-Based Immunotherapy","volume":"9","author":"Davari","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CJI.0000000000000456","article-title":"Enhancing Efficacy of TCR-Engineered CD4+ T Cells Via Coexpression of CD8\u03b1","volume":"46","author":"Anderson","year":"2023","journal-title":"J. Immunother."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1200\/JCO.2023.41.4_suppl.349","article-title":"Safety and Efficacy from the Phase 1 SURPASS Trial of ADP-A2M4CD8, a next-Generation T-Cell Receptor T-Cell Therapy, in Patients with Advanced Esophageal, Esophagogastric Junction, or Gastric Cancer","volume":"41","author":"Ajani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1200\/JCO.2023.41.16_suppl.11563","article-title":"The SPEARHEAD-1 Trial of Afamitresgene Autoleucel (Afami-Cel [Formerly ADP-A2M4]): Analysis of Overall Survival in Advanced Synovial Sarcoma","volume":"41","author":"Ganjoo","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1074-7613(00)80022-9","article-title":"T Cell Receptor and Coreceptor CD8\u03b1\u03b1 Bind Peptide-MHC Independently and with Distinct Kinetics","volume":"10","author":"Wyer","year":"1999","journal-title":"Immunity"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41417-020-0183-x","article-title":"Revisiting the Role of CD4+ T Cells in Cancer Immunotherapy\u2014New Insights into Old Paradigms","volume":"28","author":"Tay","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Sillito, F., Holler, A., and Stauss, H.J. (2020). Engineering CD4+ T Cells to Enhance Cancer Immunity. Cells, 9.","DOI":"10.3390\/cells9071721"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/imm.12941","article-title":"The Opposing Roles of CD4+ T Cells in Anti-tumour Immunity","volume":"154","author":"Ahrends","year":"2018","journal-title":"Immunology"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1126\/science.1083317","article-title":"Defective CD8 T Cell Memory Following Acute Infection without CD4 T Cell Help","volume":"300","author":"Sun","year":"2003","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nbt.4090","article-title":"Driving T-Cell Immunotherapy to Solid Tumors","volume":"36","author":"Garber","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"32786","DOI":"10.1074\/jbc.M102498200","article-title":"The Human CD8 Coreceptor Effects Cytotoxic T Cell Activation and Antigen Sensitivity Primarily by Mediating Complete Phosphorylation of the T Cell Receptor Zeta Chain","volume":"276","author":"Purbhoo","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1056\/NEJMoa0800251","article-title":"Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1","volume":"358","author":"Hunder","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.1200\/JCO.2015.65.5142","article-title":"T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined with Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression","volume":"34","author":"Chapuis","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"27491","DOI":"10.1074\/jbc.M500555200","article-title":"Interaction between the CD8 Coreceptor and Major Histocompatibility Complex Class I Stabilizes T Cell Receptor-Antigen Complexes at the Cell Surface","volume":"280","author":"Wooldridge","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"991","DOI":"10.4049\/jimmunol.177.2.991","article-title":"CD8 Alpha Coreceptor to Improve TCR Gene Transfer to Treat Melanoma: Down-Regulation of Tumor-Specific Production of IL-4, IL-5, and IL-10","volume":"177","author":"Willemsen","year":"2006","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/sj.gt.3302388","article-title":"Redirecting Human CD4+ T Lymphocytes to the MHC Class I-Restricted Melanoma Antigen MAGE-A1 by TCR Alphabeta Gene Transfer Requires CD8alpha","volume":"12","author":"Willemsen","year":"2005","journal-title":"Gene Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"S620","DOI":"10.1016\/j.annonc.2023.09.2158","article-title":"1019O Clinical and Translational Data from the Phase I SURPASS Trial of ADP-A2M4CD8 T Cell Receptor (TCR) T Cell Therapy Alone or Combined with Nivolumab in Solid Tumors","volume":"34","author":"Garcia","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_92","unstructured":"Adaptimmune (2023, June 12). A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination with Nivolumab in Subjects with Recurrent Ovarian Cancers, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05601752."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1038\/s41571-020-0347-5","article-title":"T Cell-Engaging Therapies\u2014BiTEs and Beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-021-01115-0","article-title":"T-Cell Receptor-Based Therapy: An Innovative Therapeutic Approach for Solid Tumors","volume":"14","author":"Tsimberidou","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Arnaud, M., Bobisse, S., Chiffelle, J., and Harari, A. (2021). The Promise of Personalized TCR-Based Cellular Immunotherapy for Cancer Patients. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.701636"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"eabc8697","DOI":"10.1126\/science.abc8697","article-title":"Targeting a Neoantigen Derived from a Common TP53 Mutation","volume":"371","author":"Hsiue","year":"2021","journal-title":"Science"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.molimm.2005.03.007","article-title":"Induction of Regular Cytolytic T Cell Synapses by Bispecific Single-Chain Antibody Constructs on MHC Class I-Negative Tumor Cells","volume":"43","author":"Offner","year":"2006","journal-title":"Mol. Immunol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment","volume":"31","author":"Seckinger","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-Cell Maturation Antigen \u00d7 CD3 Bispecific Antibody, in Patients with Relapsed or Refractory Multiple Myeloma (MajesTEC-1): A Multicentre, Open-Label, Single-Arm, Phase 1 Study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00280-015-2728-5","article-title":"A Phase I Trial of Intravenous Catumaxomab: A Bispecific Monoclonal Antibody Targeting EpCAM and the T Cell Coreceptor CD3","volume":"75","author":"Dittrich","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_104","unstructured":"Immunocore Ltd. (2023, December 31). A Phase II Randomized, Open-Label, Multi-Center Study of the Safety and Efficacy of IMCgp100 Compared with Investigator Choice in HLA-A*0201 Positive Patients with Previously Untreated Advanced Uveal Melanoma, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03070392."},{"key":"ref_105","unstructured":"Immunocore Ltd. (2023, December 31). Phase 1\/2 Study of IMC-F106C in Advance PRAME-Positive Cancers, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04262466."},{"key":"ref_106","unstructured":"Immunocore Ltd. (2023, December 31). A Phase I\/II Study of IMCnyeso, HLA-A*0201-Restricted, NY-ESO-1- and LAGE-1A-Specific Soluble T Cell Receptor and Anti-CD3 Bispecific Molecule, in HLA-A*0201 Positive Patients with Advanced NY-ESO-1 and\/or LAGE\u20141A Positive Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03515551."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/s41587-022-01282-6","article-title":"First Soluble TCR Therapy Opens \u2018New Universe\u2019 of Cancer Targets","volume":"40","author":"Dolgin","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients with Metastatic Uveal Melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-Redirected Tumor Cell Killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e22891","DOI":"10.4161\/onci.22891","article-title":"ImmTACs","volume":"2","author":"Oates","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_112","first-page":"1552","article-title":"1397 CDR404, an Antibody-Based Bispecific & Bivalent T-Cell Engager Targeted against MAGE-A4, for Squamous Non-Small Cell Lung Cancer (SQ-NSCLC)","volume":"11","author":"Vrohlings","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_113","unstructured":"Immunocore Ltd. (2023, December 31). A Phase 1\/2 First-in-Human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination with Atezolizumab in HLA-A*0201-Positive Patients with Advanced MAGE-A4-Positive Cancer, Available online: https:\/\/clinicaltrials.gov\/study\/NCT03973333."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"S1411","DOI":"10.1016\/j.annonc.2021.10.109","article-title":"91P Phase I Dose Escalation of IMC-C103C, a CD3\u00d7MAGE-A4 T-Cell Receptor (TCR) Bispecific Protein","volume":"32","author":"Davar","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"100269","DOI":"10.1016\/j.iotech.2022.100269","article-title":"157P Phase I Expansion of IMC-C103C, a MAGE-A4\u00d7CD3 ImmTAC Bispecific Protein, in Ovarian Carcinoma","volume":"16","author":"Sweis","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.pharmthera.2016.06.010","article-title":"Chimeric Antigen Receptor-Modified T Cells for the Treatment of Solid Tumors: Defining the Challenges and next Steps","volume":"166","author":"Beatty","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e1055061","DOI":"10.1080\/2162402X.2015.1055061","article-title":"In Situ Immunization by Bispecific Antibody Targeted T Cell Therapy in Breast Cancer","volume":"5","author":"Thakur","year":"2015","journal-title":"Oncoimmunology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1007\/s00262-011-1056-9","article-title":"In Vitro Synthesis of Primary Specific Anti-Breast Cancer Antibodies by Normal Human Peripheral Blood Mononuclear Cells","volume":"60","author":"Thakur","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a Titin-Derived HLA-A1-Presented Peptide as a Cross-Reactive Target for Engineered MAGE A3-Directed T Cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy","volume":"36","author":"Morgan","year":"2013","journal-title":"J. Immunother."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Montemurro, A., Schuster, V., Povlsen, H.R., Bentzen, A.K., Jurtz, V., Chronister, W.D., Crinklaw, A., Hadrup, S.R., Winther, O., and Peters, B. (2021). NetTCR-2.0 Enables Accurate Prediction of TCR-Peptide Binding by Using Paired TCR\u03b1 and \u03b2 Sequence Data. Commun. Biol., 4.","DOI":"10.1038\/s42003-021-02610-3"},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Jokinen, E., Huuhtanen, J., Mustjoki, S., Heinonen, M., and L\u00e4hdesm\u00e4ki, H. (2021). Predicting Recognition between T Cell Receptors and Epitopes with TCRGP. PLoS Comput. Biol., 17.","DOI":"10.1371\/journal.pcbi.1008814"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0198-8859(01)00298-1","article-title":"Analysis of the Frequencies of HLA-A, B, and C Alleles and Haplotypes in the Five Major Ethnic Groups of the United States Reveals High Levels of Diversity in These Loci and Contrasting Distribution Patterns in These Populations","volume":"62","author":"Cao","year":"2001","journal-title":"Hum. Immunol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"e000316","DOI":"10.1136\/jitc-2019-000316","article-title":"Phase II Study of \u03b1-Galactosylceramide-Pulsed Antigen-Presenting Cells in Patients with Advanced or Recurrent Non-Small Cell Lung Cancer","volume":"8","author":"Toyoda","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e23432","DOI":"10.4161\/onci.23432","article-title":"Immunotherapy with Artificial Adjuvant Vector Cells","volume":"2","author":"Fujii","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"(1978). The Immunological Basis of Endotoxin-Induced Tumor Regression. Requirement for a Pre-Existing State of Concomitant Anti-Tumor Immunity. J. Exp. Med., 148, 1560\u20131569.","DOI":"10.1084\/jem.148.6.1560"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"(1981). Mechanisms of Anti-Tumor Action of Corynebacterium Parvum. I. Potentiated Tumor-Specific Immunity and Its Therapeutic Limitations. J. Exp. Med., 154, 609\u2013620.","DOI":"10.1084\/jem.154.3.609"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1158\/2159-8290.CD-17-1417","article-title":"Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma","volume":"8","author":"Melchiori","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s40425-019-0762-2","article-title":"Systemic and Local Immunity Following Adoptive Transfer of NY-ESO-1 SPEAR T Cells in Synovial Sarcoma","volume":"7","author":"Ramachandran","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and Biomarkers of Severe Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor\u2013Modified T-Cell Therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00262-022-03287-1","article-title":"Lymphodepleting Chemotherapy Practices and Effect on Safety and Efficacy Outcomes in Patients with Solid Tumours Undergoing T Cell Receptor-Engineered T Cell (TCR-T) Therapy: A Systematic Review and Meta-Analysis","volume":"72","author":"Owen","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/14712598.7.6.893","article-title":"T-Cell Receptor Gene Transfer by Lentiviral Vectors in Adoptive Cell Therapy","volume":"7","author":"Bobisse","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/cei.12610","article-title":"Clonotypically Similar Hybrid A\u03b2 T Cell Receptors Can Exhibit Markedly Different Surface Expression, Antigen Specificity and Cross-Reactivity","volume":"180","author":"Motozono","year":"2015","journal-title":"Clin. Exp. Immunol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","article-title":"CRISPR-Mediated TCR Replacement Generates Superior Anticancer Transgenic T Cells","volume":"131","author":"Legut","year":"2018","journal-title":"Blood"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1002\/JLB.5A0817-314R","article-title":"TCR Modifications That Enhance Chain Pairing in Gene-Modified T Cells Can Augment Cross-Reactivity and Alleviate CD8 Dependence","volume":"103","author":"Spear","year":"2018","journal-title":"J. Leukoc. Biol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2217\/imt.15.19","article-title":"Exploiting Cytokines in Adoptive T-Cell Therapy of Cancer","volume":"7","author":"Petrozziello","year":"2015","journal-title":"Immunotherapy"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1172\/JCI32103","article-title":"Adoptive Transfer of Effector CD8+ T Cells Derived from Central Memory Cells Establishes Persistent T Cell Memory in Primates","volume":"118","author":"Berger","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nri1842","article-title":"Adoptive Immunotherapy for Cancer: Building on Success","volume":"6","author":"Gattinoni","year":"2006","journal-title":"Nat. Rev. Immunol."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely Related T-Memory Stem Cells Correlate with In Vivo Expansion of CAR.CD19-T Cells and Are Preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1172\/JCI86000","article-title":"Clinical Responses with T Lymphocytes Targeting Malignancy-Associated \u03ba Light Chains","volume":"126","author":"Ramos","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.biotechadv.2018.12.002","article-title":"Standardizing CAR-T Therapy: Getting It Scaled Up","volume":"37","author":"Dai","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4049\/jimmunol.2300642","article-title":"Engineering Challenges and Opportunities in Autologous Cellular Cancer Immunotherapy","volume":"212","author":"Foley","year":"2024","journal-title":"J. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.20.02224","article-title":"T-Cell Therapy for Lymphoma Using Nonengineered Multiantigen-Targeted T Cells Is Safe and Produces Durable Clinical Effects","volume":"39","author":"Vasileiou","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/1078-0432.CCR-15-1070","article-title":"Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer","volume":"22","author":"Moon","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ijc.29401","article-title":"Permissive Expansion and Homing of Adoptively Transferred T Cells in Tumor-Bearing Hosts","volume":"137","author":"Perez","year":"2015","journal-title":"Int. J. Cancer"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e24850","DOI":"10.4161\/onci.24850","article-title":"Trial Watch: Immunostimulatory Cytokines","volume":"2","author":"Vacchelli","year":"2013","journal-title":"Oncoimmunology"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Hong, D.S., Butler, M.O., Pachynski, R.K., Sullivan, R., Kebriaei, P., Boross-Harmer, S., Ghobadi, A., Frigault, M.J., Dumbrava, E.E., and Sauer, A. (2022). Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients with MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.818679"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/413\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:41Z","timestamp":1759919801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/3\/413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,26]]},"references-count":148,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["cancers17030413"],"URL":"https:\/\/doi.org\/10.3390\/cancers17030413","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,26]]}}}